and keloids SM

®

VISIONNow You Can See What You Treat

SRT-100 VISION™

Superficial Radiotherapy

See what you Treat with High-Frequency Ultrasound Image Guidance (IGSRT)

As the market leader in non-invasive non-melanoma skin

cancer (NMSC) treatment, Sensus Healthcare is proud

to introduce another proven technology to Cutaneous

Radiation Oncology — High-Frequency Ultrasound for

imaging and Image Guidance. With this exclusive feature

of the SRT-100 Vision™, you can now see and assess the

lesions you treat like never before.

As illustrated in the images to the right, High-Frequency

Ultrasound Image Guidance at 22 MHz and 75 MHz

enables you to examine lesions at the micron level to

assist you in determining the proper protocols for treating

your patients.

• Define lesion boundaries

and margins for treatment

• Determine the optimal

treatment energy

and applicator size

HIGH-FREQUENCY ULTRASOUND IMAGING

BCC on left cheek

Patient background: Female, 74 years old, menopause. Basal cell carcinoma (histologically confirmed) located on the left cheek, on the border with the upper part of the nasolabial fold.

75 MHz scan data: Epidermis thickness increased to 220-250 microns (in control contralateral area 110-120 microns). External contour of the epidermis is uneven (rough), acoustic density of the epidermis is irregular. Sub-epidermal echo-negative area of 80-350 microns is visible throughout lesion area. Dermis thickness increased to 1,750 microns (in control contralateral area 1,200-1,300 microns), with acoustic density decreased to 24 (in control contralateral area 32).

BCC on left scapula

Patient background: Female, 56 years old, menopause. BCC on forehead was surgically removed (histologically confirmed) two years prior.BCC lesion located on left scapula area.

75 MHz scan data: Epidermis thickness increased to 300-350 microns (in control contralateral area 125-145 microns). External contour of the epidermis uneven (rough), acoustic density of the epidermis is irregular. Sub-epidermal echo-negative area of 300-550 microns is visible throughout lesion area. Dermis thickness increased to 2,650 microns (in control contralateral area 1,900-2,000 microns), with acoustic density decreased to 16 (in control contralateral area 28).

Sensus Healthcare is the proud recipient of the Frost & Sullivan 2014 North American New Product Innovation Leadership Award in Non-Melanoma Skin

Cancer Therapy. This coveted award recognizes Sensus’s commitment to superficial radiotherapy (SRT) and the positive outcomes our non-invasive therapy solutions afford the clinical professionals and patients we serve.

2014

NORTH AMERICANNON-MELANOMA SKIN CANCER THERAPY

NEW PRODUCT INNOVATION LEADERSHIP AWARD

SUPERFICIAL RADIOTHERAPY (SRT)

There is no better way to start treating NMSC and Keloids than with Superficial Radiotherapy (SRT)

For more than fifty years, Superficial Radiotherapy (SRT)

has been acknowledged as the “Gold Standard” for the

non-invasive treatment of non-melanoma skin cancer.

It is now also FDA cleared as a critical adjunct to surgery

for the prevention of Keloids.

The award winning innovative design of the SRT-100

Vision™, by Sensus Healthcare, offers important features

that make it the preferred treatment choice:

Three treatment modes let you tailor the energy to the

lesion type and body region.

50 kV – lesions on the lower extremities and scalp

70 kV – lesions on general areas of the body,

especially squamous cell carcinomas

100 kV – the power to effectively cure and

prevent Keloids

Family of applicators (1 cm to 18 x 8 cm)

let you match the NMSC or Keloid

treatment area.

True mobile design lets you take the

SRT-100 Vision™ to your patients and more

efficiently utilize your facilities – the treatment

room next door, another department in

the hospital or across town. All critical

components are onboard – simply plug

and play!

Keloid preventative – the SRT-100

Vision™ achieves Keloid cure rates

of up to 100% when combined

with surgery.

Moderately differentiated SCC on scalp. 74 year old male. 12 Fx @ 396.2 cGy. Total dose: 4,754 cGy. TDF: 112

Nodulo-infiltrative BCC on left ala. 84 year old female. 13 Fx @ 360.8 cGy Total dose: 4,690 cGy. TDF: 103

Well-differentiated SCC on leg. 88 year old female.15 Fx @ 337.2 cGy. Total dose: 5,058 cGy. TDF: 101

Well-differentiated SCC on leg. 84 year old female. 15 Fx @ 337.2 cGy. Total dose: 5,058 cGy. TDF: 101

Keloids on left shoulder. 34 year old male. After photo:post excision and SRT at 6 months. Total dose: 1,600 cGyin 2 fractions within 72 hours of excision procedure.

BEFORE AFTER

“ Have you told your patients the good news?”

UT

15 cm SSD 25 cm SSD 30 cm SSD

1 cm 1.5 cm 2.0 cm 2.5 cm 3 cm 4 cm 5 cm 7.3 cm 10 cm 12.7 cm 18x8 cm

A High-Frequency Image Guidance system (22 to 75 MHz at 72 µm to 21 µm, respectively)

B Contemporary and elegant patient friendly design offers open and easy access

C Multi-axis positioning arm provides a full range of motion for patient preparation and positioning

D Multiple treatment techniques for a wide range of applications 50 kV at 10 mA – scalp and lower extremities 70 kV at 10 mA – general body 100 kV at 8 mA – Keloids X-Ray output: 650 cGy per minute at 15 cm SSD

E 30”x 30” footprint allows siting almost anywhere

F Mobility engineered, with all subsystems built-in including cooling system and high-voltage generator

G Medical grade wheels make the system easy to relocate

H 110 V AC wall power and minimal shielding requirements make siting simple

I RADCheck™ QC automatically

confirms system calibration each time the system is initiated. This assures the patient is getting the correct dose and eliminates the need for un-scheduled calibrations

J Audio/visual monitor allows constant bi-directional patient communication

K Patient safety features throughout the system maintain safe, consistent and reliable operation, including: door interlocks, X-Ray light driver, automatic filter selection, emergency stop switches, RADCheck™, timer redundancy, and hardware safety circuitry all ensure a safe and faultless workflow

L State-of-the-art architecture delivers robust computing power and offers expansion capabilities for ancillary modules and hybrid therapeutic and imaging modalities

M Patient and workflow scheduler, plus electronic patient record management system, are built in to help optimize workflow efficiency

N EMR, RTP, HIS and RIS integration ready

O Medical grade X-Ray tube assures years of reliable service when properly maintained

P Automatic Al filter magazine applies the correct filter to match the selected energy

Q Laser positioning system for precise beam port positioning and re-positioning on the treatment area

R Digital camera provides lesion photo-registration and treatment video recording for

patient records. An integrated record and verify application

streamlines workflow and interconnects with enterprise EMR, RTP, and HIS/RIS systems

S LED lighting brightly illuminates the treatment area for positioning and documentation

T Touchscreen control console

and control module provide the controls and indicators to set up, initiate, monitor and terminate exposures

The control panel and control module can be located remotely.

U Live video feeds of the patient and treatment area are displayed to verify patient/procedure readiness

V Precision applicators are available for treating a wide range of NMSC lesions and Keloids from 1 cm to 18 x 8 cm

W See-through safety applicator tips allow visibility of the treated area for accurate beam positioning

VISIONSRT-100 VISION™

Powerful performance. Versatile design

V

B

C

D

E

F

G

H

J

K

L

M

N

O

P

W

A

A

I

Q

R

S

VISIONSRT-100 VISION™

Become a Total Solutions provider

NMSC and Skin of Color represent large under-served

markets for your practice, institution and healthcare

system. Become a total skin solutions provider, and

expand your community footprint in these growing

market segments, with the SRT-100 Vision™.

The NMSC Epidemic

NMSC is the largest and fastest growing segment

within cancer representing more than 2.5 times all

other cancers combined. 4 million cases of NMSC

are diagnosed in the U.S. every year. And, that

number is expected to grow more than 50% to over

6 million cases by the year 2020.

The SRT-100 Vision™ is the “Game Changer” you need

to complement your existing oncology, dermatology

and surgery services and build a

loyal cancer treatment patient

base for NMSC. SRT is the most

effective non-invasive

treatment for NMSC, with a

95%+ cure rate1. SRT has

been an established

treatment for more

than 50 years.

40,000+ NMSC

patients have

been treated

on the SRT-

100 platform.

Ethnic Skin Types and Keloids – The Solution

It is estimated that more than 18 million people of

ethnic skin types are affected with Keloids in the U.S.

Of those, 11 million seek treatment while many of the

remaining 7 million do not think there is a treatment or

cure available.

Keloids are chronic non-malignant tumors that form at

the site of skin trauma, such as piercings, accidents,

or general surgery, including: OB/GYN, orthopedics,

cardiology, plastic surgery, cutaneous surgery, etc.

Keloids recur in up to 90% of cases2 when surgery alone

is used for removal, which is why many people have

given up hope and may not seek treatment.

Offer hope to Keloid sufferers. The recurrence of Keloids

is reduced to as low as 10%2 (0% in many cases) when

using a protocol combining surgery with SRT – resulting

in up to 100% cure rate.

The SRT-100 Vision™ has been FDA cleared for the

treatment of Keloids following surgical removal. It also

makes possible prophylactic treatment for Keloids to

general surgery patients who are predisposed to their

development. Offering a “Keloid Cure” serves as an

ideal base on which to build a strong ethnic skin

footprint in your community. In addition to the

full range of standard applicators, a unique

18 x 8 cm (at 30 cm SSD)

applicator has been

engineered by

Sensus Healthcare

exclusively for

the treatment

of longitudinal

incisions, such

as a cesarean-

section and

sternotomy.

Deliver high value at every level The SRT-100 Vision™ offers patients, physicians, institutions and healthcare systems great value – from better patient outcomes, to serving more patient needs, expanding your institution’s footprint in the community and reducing the overall cost of healthcare.

Non-melanoma Skin CancerValue

Proposition Keloids

• Surgery no longer has to be the only choice• Patients are demanding options to surgery• SRT provides effective treatment for all

non-melanoma skin cancers• Proven alternative for patients with pre-existing

conditions• 95%+ cure rate1 - same as surgery without the

side effects• No cutting or bleeding• No sutures, bandages or scarring• No pain or chronic numbness• No follow-up reconstructive surgery• Treatment time less than one minute• No disruption to normal lifestyle and activities

Patient • Now there is a cure for Keloids• Patients no longer have to live with this chronic

condition• High cure rate (90% to 100%)2

• Low recurrence rate (0%-10%)• Also add SRT prophylactically to your general

surgery protocol to protect Keloid susceptible patients:

- trauma, cardiothoracic, orthopedic, OB/GYN, etc.

• Proven non-invasive alternative to surgery for treating patients with wound closure and co-morbidity concerns, such as diabetes, cardiac disease, as well as the elderly

• Excellent results on the lower extremities and scalp• Minimizes the risk of infections• Reduces treatment time• User friendly• No pharmaceuticals or consumables• Your patients trust you – now they will thank you

Physician • Serve the ethnic skin market in your community• Better cosmetic results – be proud of your

closure signature

• Skin is the largest segment of the cancer treatment market

• Expand your footprint in the community with a total solution to cancer care

• Provide treatment solutions that are not currently offered

• Create new services in a very large market• Happy patients are likely to return for other

treatment services when needed and spread the “good news” throughout the community

Institution • Address the needs of the ethnic skin market that are not currently served

• Develop a general surgery protocol to treat Keloid-prone patients

- trauma, cardiothoracic, orthopedic, OB/GYN, etc.

• Create new services in a very large market

• No ongoing costs such as reconstructive surgery and infection

• Better outcomes with lower risk equals exceptional quality of care

• Cost effective state-of-the-art technology with proven outcomes

• Quality-based medicine with better results and fewer repeats

HealthcareSystem

• 90% to100% cure rate - low risk of having to remove again in the future

• Better outcomes with lower risk equals exceptional quality of care

• Cost effective state-of-the-art technology with proven outcomes

• Quality-based medicine with better results and fewer repeats

“Patients who look better, feel better.”

4.50

4.00

3.50

3.00

2.50

2.00

1.50

1.00

0.50

0.00

NMSC

Prosta

te

Breast

Lung

Colon

Lym

phoma

Mela

noma

Oth

er

Grow your footprint in your community by

offering proven outcomes for NMSC

and ethnic skin types with the

SRT-100 Vision™. Patients

who cannot, or wish

not to, undergo

surgery will thank

you for offering them

this non-invasive

alternative – with the same high

cure rate as surgery – without the adverse

effects. With the SRT-100 Vision™ you can

also build a strong reputation for skin care

excellence by giving Keloid sufferers the cure

they have long searched for.

Contact Sensus Healthcare to find out how

the SRT-100 Vision™ can help elevate your

successful skin treatment program.

SRT-100 VISION™

Build a strong reputation for skin care excellence

World HeadquartersSensus Healthcare

851 Broken Sound Parkway NW #215Boca Raton, FL 33487

P: 561-922-5808 Toll free: 800-324-9890F: 561-948-2071

E: info@sensushealthcare.comW: sensushealthcare.com

2014

NORTH AMERICANNON-MELANOMA SKIN CANCER THERAPY

NEW PRODUCT INNOVATION LEADERSHIP AWARD

1. Superficial x-ray in the treatment of basal and squamous cell carcinomas:A viable option in select patients. Cognetta, Armand B. et al. Journal of theAmerican Academy of Dermatology vol. 67 issue 6 December, 2012.p. 1235-1241

2. The treatment of hypertrophic scars and keloids. Berman B, Flores F. Eur J Dermatol 1998 Dec;8(8):591-5 Department of Dermatology and Cutaneous Surgery, University of Miami School of Medicine, Miami, FL 33136, USA

Represented internationally by:

CanadaAIC8-611 Wonderland Road N Suite 363London, Ontario Canada N6H -5H7P: 226-785-9330E: maddley@earthlink.net

ChinaJTT-CuratioShangzhuang Century Industrial ParkLuquan, ShangzhuangHebei, China 050200P: +86311-82200510F: +86311-82200516E: jtt@jtt-ems.com

EuropeRT-Idea B.V.Riperwalden 18406 ET TijnjeThe NetherlandsP: +31-513-411-892E: info@rt-idea.com

RussiaMedical Engineering Solutions, LLCRussian Federation, 142784,Moscow Region, Leninsky Dist., Moskovsky,Solnechnaya St., 15P/F: (499) 955-31-41E: Info@ooomir.ru

Sensus Healthcare reserves the right to modify the system design and specifications described herein without prior notice. Some configurations described herein are optional.

SRT-100 Vision and RADCheck are trademarks of Sensus Healthcare. © 2014 Sensus Healthcare. All rights reserved.

MKT-SRT-024

Manufactured in the United States

and keloids SM

®